As of June 2026, there is no publicly verified net worth figure for Kimon Angelides. The question of Kimon Angelides's personal financial situation often leads people to ask about Angie Katsanevas's husband net worth, but no verified public figure is available Angie Katsanevas husband net worth. Based on available public data, a reasonable working estimate sits somewhere between $1 million and $10 million, though significant uncertainty pulls that range in both directions. His wealth is tied to a career building and leading healthcare startups, and the collapse of his most prominent recent venture, FemTec Health, almost certainly reduced whatever peak value he may have held.
Kimon Angelides Net Worth: Estimate, Sources, and Method
Dimitri Papadopoulos
23 Jun 2026
Who exactly is Kimon Angelides?
The Kimon Angelides referenced in most current public records is Kimon Jerry Angelides, PhD, a Houston-based entrepreneur and biomedical scientist. He holds a doctorate in bio-organic chemistry and has built a career at the intersection of healthcare, medical devices, and health technology. This is not to be confused with any other individual who might share a similar name.
The public record for this specific person is traceable through SEC EDGAR filings, [FDA documentation (where he appears as Chief Scientific Officer on blood glucose monitoring paperwork)](https://www. accessdata. fda. gov/cdrh_docs/pdf13/K133584.
pdf), federal court cases (including Kimon Angelides v. Baylor College of Medicine, 5th Cir. 1997), and multiple startup press releases. His full name, Kimon Jerry Angelides, also appears in UK company records for BEAUTYCOM UK LIMITED, which connects to his later FemTec Health work.
There is also a documented history with Baylor College of Medicine that includes an HHS/ORI misconduct investigation involving grant applications and research papers from his time running a laboratory there. That history is part of the public record and relevant to understanding why his post-academic career shifted entirely into commercial entrepreneurship.
The net worth estimate and range
Working range: $1 million to $10 million, with the most likely scenario sitting toward the lower half of that band as of mid-2026. He does not appear on any Forbes billionaire or high-net-worth list, and he is not included in Wikipedia's list of Greeks by net worth, which draws directly from Forbes annual assessments. That absence is itself informative. You can also look up theodore angelopoulos net worth using similar public-record signals and credible financial reporting.
The upper end of the range reflects potential residual equity from successful earlier ventures, particularly EosHealth and its connection to Livongo Health, which went public and was eventually acquired by Teladoc for approximately $18.5 billion in 2020. If Angelides held meaningful equity from those early-stage years, that could represent a significant payout. This is why the discussion of Angelos family net worth focuses on what those earlier equity stakes may have been worth rather than any confirmed figure. The lower end of the range reflects the FemTec Health collapse, unpaid obligations, and the legal and reputational costs that come with a company winding down through an assignment for the benefit of creditors.
Career and wealth sources
Angelides has founded or co-founded at least six healthcare companies over roughly three decades. Global Cosmetic Industry and his own public bio identify EosHealth (later connected to Livongo), Diabetes America, MAB Generation, and BioNexus Ventures as part of that portfolio. Diabetes America is particularly notable: he reportedly grew it from one employee to over 200 in four years, which signals genuine operational execution and likely some return on that effort, whether through sale, investment, or compensation. Kimon Angelides’s about.
me public profile claims he founded or ran EosHealth (later connected to Livongo), Diabetes America, MAB Generation, and BioNexus Ventures, and it says he grew Diabetes America from one employee to more than 200 in four years about. me public profile claims he founded or ran EosHealth and Diabetes America.
Many readers apply the same kind of indirect, deal-based logic when estimating Giorgos Angelopoulos net worth return on that effort.
His most recent major venture was FemTec Health, launched in May 2020 and positioned as a direct-to-consumer women's health platform. FemTec acquired Birchbox in July 2021, a deal that attracted significant press attention. Angelides served as both founder and executive chairman, and later as CEO. The company raised external funding and made acquisitions, which suggests he was not the sole capital source and that dilution of his personal ownership stake was likely over multiple funding rounds.
FemTec Health ultimately wound down through an assignment for the benefit of creditors, an out-of-court process similar to Chapter 7 bankruptcy. Axios reporting on FemTec Health cited layoffs and debt, and it references founder Kimon Angelides acknowledging struggles in an interview Axios reporting revealed layoffs and debt. Axios reporting revealed layoffs, debt, and allegations that nearly $2.1 million owed to former Birchbox CEO Katia Beauchamp following the acquisition was never paid. These are signals of a company that burned through capital without generating sufficient returns, which typically wipes out founder equity.
How the estimate is built from public data
Without private financial disclosures, the estimate is built from a set of indirect signals. Here is what the public record actually tells us.
| Signal | What it suggests | Strength |
|---|---|---|
| EosHealth / Livongo connection | Potential early-stage equity in a company that grew into a multi-billion acquisition | Moderate — unclear how early or how large his stake was |
| Diabetes America growth (1 to 200 employees) | Operational success and likely financial return via sale or compensation | Moderate — no reported sale price in public records |
| FemTec Health collapse via creditors' assignment | Founder equity likely wiped out; personal liability exposure possible | Strong negative signal |
| $2.1M unpaid obligation to Birchbox CEO | Company-level insolvency at the time of wind-down | Strong negative signal |
| SEC EDGAR director nominee appearance | Board-level involvement in at least one public or SPAC vehicle | Weak positive — no confirmed compensation or stake size |
| UK company (BEAUTYCOM UK LIMITED) association | International business activity connected to FemTec/beauty health | Weak — no financial data attached |
| No Forbes or Wikipedia net worth listing | Wealth almost certainly below $100M threshold for notable Greek wealth lists | Moderate negative signal |
The Livongo connection is the most important unknown in this estimate. Livongo went public in 2019 at a valuation of around $2.5 billion and was acquired by Teladoc for roughly $18.5 billion in 2020. If Angelides held even a fraction of a percent of equity from the EosHealth days, that could mean tens of millions of dollars. This helps explain how analysts approach estimating Panagiotis Angelopoulos net worth from public signals rather than private disclosures. But the public record does not confirm the size or duration of his ownership stake, and early-stage founders often see heavy dilution before an exit.
Data gaps and credibility check
The biggest gap is equity documentation. There are no publicly available cap table records, Schedule 13D filings, or S-1 disclosures that clearly show Angelides's ownership percentage in any of his companies at the time of exit or funding. The Livongo connection is mentioned in his public bio and on his about.me profile, but there is no independent confirmation of what that stake was worth.
The HHS/ORI misconduct findings from his Baylor College of Medicine years are a credibility consideration. They are government-adjudicated findings on public record, and they are relevant context for evaluating how to weight his self-reported professional narrative. That said, the misconduct findings relate to academic research conduct, not to his business dealings or financial affairs directly.
The FemTec Health collapse is well-documented through Axios reporting, court filings, and the creditors' assignment process. That documentation is credible and recent. It confirms that his most recent major venture did not produce a positive financial outcome and likely generated liabilities.
Self-reported bios (about.me profiles, podcast appearances) are useful for mapping career history but should not be treated as verified financial disclosures. Dun & Bradstreet and Buzzfile listings confirm the company and his role but add nothing to the net worth picture.
What could move the number up or down
- Confirmed Livongo equity payout: If records emerge showing he held equity at the time of the Teladoc acquisition, the estimate could move significantly higher, potentially into the $10M to $50M range or beyond.
- New venture success: Angelides has a pattern of serial founding. A new healthcare startup that raises significant capital or exits would change the picture quickly.
- Legal liability from FemTec wind-down: Creditor claims, unresolved litigation, or personal guarantee obligations from FemTec could reduce personal net worth further.
- Real estate or private asset discovery: Property records in Texas or the UK could reveal holdings not visible in current public data.
- Additional court filings: Federal or state litigation tied to FemTec's collapse could surface financial disclosures that clarify his current position.
- Greek business interests: If he holds any assets or business interests in Greece that have not been publicly reported, those would shift the estimate in either direction.
How to verify and keep tracking this
If you want to go deeper on this estimate yourself, here are the most productive places to look.
- SEC EDGAR (sec.gov): Search 'Kimon Angelides' to find any filings where he appears as a director, officer, or beneficial owner. The Petra Acquisition filing is one confirmed result. Look for Schedule 13D/G or proxy disclosures that show ownership percentages.
- PACER (federal court records): His 5th Circuit case history (Kimon Angelides v. Baylor College of Medicine, 117 F.3d 833) is a confirmed anchor. New litigation tied to FemTec Health would show up here, and financial disclosures sometimes appear in bankruptcy-adjacent proceedings.
- Texas Secretary of State business filings: FemTec Health, Diabetes America, and other Houston-based entities can be searched here to confirm formation dates, registered agents, and corporate structure.
- HHS Office of Research Integrity (ori.hhs.gov): The ORI case record for Kimon J. Angelides is publicly accessible and provides verified background on the Baylor-era findings.
- Companies House (UK, companieshouse.gov.uk): BEAUTYCOM UK LIMITED and any other UK entities tied to Kimon Jerry Angelides can be searched here for director appointments, filings, and financial statements.
- Google News alerts: Set an alert for 'Kimon Angelides' to catch any new media coverage, court filings, or business announcements. Axios has covered him closely, so their health/tech vertical is worth monitoring.
- Crunchbase and PitchBook: These platforms track startup funding rounds. If Angelides launches a new venture or if historical FemTec Health funding rounds are documented, equity dilution context will be visible there.
For comparison, this site covers other notable Greek business figures including members of the Angelopoulos family and entrepreneurs across sectors where public financial data is similarly patchy. The same methodology applies: anchor on verified public filings, weight media reports by the outlet's track record, and treat self-reported bios as career maps rather than financial disclosures. The honest answer on Kimon Angelides right now is that the public record supports an estimate but not a precise figure, and the most important data point (his Livongo-era equity) remains undocumented in publicly accessible sources. If you are also tracking angelos frangopoulos net worth, you can apply the same approach of relying on filings and documented equity events rather than rumors.
FAQ
Why is there no exact publicly verified net worth for Kimon Angelides?
No, because his personal wealth has not been tied to a verified, public cap table or personal holdings disclosure. The range in the article reflects uncertainty in equity ownership and dilution, and a later business wind-down typically eliminates most founder equity, even if the founder remains a public-facing executive.
How can I avoid confusing Kimon Angelides with someone else when researching?
Start by validating identity first, then map each company to a specific corporate record and ownership event (funding round, merger, acquisition, or liquidation). For Kimon Jerry Angelides, mixing up similarly named individuals is a common error that can lead to importing the wrong filings or press references.
What specific information would most improve the net worth estimate?
The most impactful missing input is documented ownership during the EosHealth to Livongo path. Without a confirmed percentage and timing, you cannot translate the Livongo valuation or Teladoc acquisition price into a reliable dollar amount for his stake.
Why can founder status still lead to a much lower personal payout than expected?
Equity can be heavily diluted between seed, Series A, later rounds, and acquisitions, so “founder” does not reliably equal “large payout.” A founder can also have preferred shares, vesting, or selling restrictions that reduce realized value compared with headline valuations.
Could Kimon Angelides have been involved in a big exit and still have a relatively low realized net worth?
Not necessarily. A company can be associated with a large exit valuation yet still produce little for a specific person if their stake was small, diluted, encumbered, or bought out differently. The article’s range treats the Livongo connection as plausible upside, but it remains unverified.
What is the most common mistake people make when estimating net worth from public info?
Because the estimate relies on indirect signals, it is easy to over-weight one data point like a company valuation or a press mention. A better approach is to weight events that reflect cash outcomes for shareholders, like documented acquisitions, distributions, or confirmed wind-down terms.
Are about.me profiles, podcasts, and bios useful for net worth research?
Self-reported bios can help build a timeline, but they should not be treated as proof of ownership percentage, compensation amounts, or liquidation results. Use them to identify companies and roles, then confirm with filings, court records, or reputable reporting tied to specific dates.
What public records should I prioritize to validate whether founder equity was wiped out or realized?
If you are trying to replicate the estimate, focus on whether any filings disclose beneficial ownership (for example, investor stake disclosures) or whether court and creditor materials indicate equity value being wiped out in the wind-down. For FemTec, the creditor assignment signals likely limited founder equity recovery.
How should I treat repeated claims across multiple websites or forums?
Yes, but it should be done carefully. If you see similar claims across sources, check whether any source provides primary identifiers (company registration details, specific corporate entities, or named directors). Repeating the same unverified assertion is not independent verification.
Is it possible to create a more precise model estimate even without cap table disclosures?
If you want a more precise estimate, you can attempt a scenario model (low, mid, high) using assumed equity percentages at key dates and estimated dilution factors, then subtract likely dilution from subsequent funding rounds. The article explains that the crucial equity data point is missing publicly, so any scenario will still be assumption-driven.